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A C C E P T E D M A N U S C R I P T
ACCEPTED MANUSCRIPT 3 Childhood vaccination forestalls an estimated 2 to 3 million deaths annually, however preventable diseases like maternal and neonatal tetanus remain a health problem in many parts of the world (1). A recent analysis of childhood mortality placed the burden of neonatal tetanus at 49,000 in 2013, accounting for 1.7% of all neonatal deaths (2) . Immunization campaigns have been pivotal in reducing the incidence of this disease (3) . Women of reproductive age are routinely given tetanus vaccine as part of prenatal care services and during campaigns in high-risk areas, while children receive three doses of diphtheriatetanus-pertussis (DTP) vaccine in the first year of life. Despite progress, the goal of the Global Vaccine Action Plan (GVAP) to achieve 90% DTP3 vaccination coverage worldwide by 2015 has remained unmet and monitoring of immunization at the country level has been recommended by the Strategic Advisory Group for GVAP (4) . A validated test of immune status that is affordable and easy to deploy would assist in monitoring immunization programs and identifying populations that are susceptible due to lack of vaccination or due to poor vaccine efficacy (5) .
Indirect ELISA is widely used in clinical settings to detect the presence of vaccine-induced anti-tetanus antibodies in either whole blood or plasma. We previously validated the use of recombinant Fragment C (rFragC) of the tetanus toxin as an alternative antigen to tetanus toxoid in ELISA (7) . We have now developed dipstick tests using rFragC as a rapid and less expensive alternative to the available commercial ELISAs. The new dipstick devices use goldconjugated rFragC to bind anti-tetanus antibodies in blood or plasma/serum. Binding Site, Birmingham, UK). While titers as low as 0.01 IU/mL could be protective an ELISA-derived value >0.16 IU/mL was found to more reliably predict protection (13) . WHO considers that a titer of 0.1-0.2 IU/mL correlates with protection in a ELISA (14) . For our analysis, we considered 0.1 IU/mL to be the immune cutoff in the TBS ELISA and assigned a value of 0.01 IU/mL or 10 IU/mL to samples that fell below or above the range of the standard curve (0.01-7.0 IU/mL). The dipstick results showed good correlation of the signal quantified (Fig. 1C, D) . This apparent discrepancy in FN's may be due to differences in the operation of the test at the two sites; independent confirmation of weak test signals was routinely done at icddr,b but was not practical at MRCG.
Whole blood testing:
The dipstick device performance with blood was initially assessed for correlation of signal strength with plasma anti-tetanus titers using USA samples (n=100) and with freshly collected samples at the Bangladesh site (n=104) (Fig. 1B) . Whole-blood dipstick results were then evaluated by eye at the two field sites (Bangladeshi Children, n=104; Gambian Children, n=143;
Gambian Adults, n=20). Nine adults and one child were non-immune by TBS ELISA. Possibly due to the operational differences at the two sites described 
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ACCEPTED MANUSCRIPT 9 We combined the results from visual readout at the two field sites for assessing the sensitivity and specificity of the dipsticks with whole blood and with plasma as substrates (Table 1) . The dipstick devices had a sensitivity >0.9 and positive predictive value of 0.99 with both plasma and whole blood from >200 tetanus-immune individuals in our study cohorts. We were able to identify 11 non-immune individuals; samples from 10 of these tested negative with our dipstick devices, yielding a specificity of 0.9. The low negative predictive value (plasma = 0.43; blood = 0.29) reflects the number of FN in our testing as well as the small number of unvaccinated individuals in our study cohorts (TN) (15) which is a limitation of the study. Our results indicate that these tetanus dipstick devices are well-suited for deployment using either plasma or blood in vaccination outreach programs, allowing the
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10 identification of non-immune or low titer individuals for whom booster shots are recommended (16). However, as is the case with using indirect ELISA as a diagnostic, individuals with anti-tetanus titers lower than 0.1 IU/mL are assessed by the dipstick devices to be non-immune although levels as low as 0.01 IU/mL are known to be protective. However, our experience has been that vaccinated individuals most commonly possess titers >0.1 IU/mL. Nevertheless, these tests hold potential for rapid and easy point of care assessment of immunity to tetanus particularly in community-based surveys, and would be effective even in resource-poor settings using a drop of blood obtained from a heel or finger prick. 
